|
|
Volumn 6, Issue 2, 2016, Pages 113-114
|
|
Venetoclax yields strong responses in CLL
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IBRUTINIB;
IDELALISIB;
OBINUTUZUMAB;
OFATUMUMAB;
PROTEIN BCL 2;
VENETOCLAX;
FUSED HETEROCYCLIC RINGS;
SULFONAMIDE;
CANCER IMMUNOTHERAPY;
CANCER PROGNOSIS;
CHROMOSOME DELETION;
CHRONIC LYMPHATIC LEUKEMIA;
GENE OVEREXPRESSION;
HUMAN;
LEUKEMIA CELL;
NEUTROPENIA;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
UPPER RESPIRATORY TRACT INFECTION;
CHROMOSOME 17;
GENETICS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
ORGANIZATION;
TREATMENT OUTCOME;
BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC;
CHROMOSOME DELETION;
CHROMOSOMES, HUMAN, PAIR 17;
CLINICAL TRIALS, PHASE II AS TOPIC;
CONGRESSES AS TOPIC;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
SULFONAMIDES;
TREATMENT OUTCOME;
|
|
EID: 84957061230
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2015-180 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|